



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
www.uspto.gov

JAN - 8 2008

Office of Regulatory Policy  
HFD - 7  
5600 Fishers Lane (Rockwall II Rm. 1101)  
Rockville, MD 20857

Attention: Beverly Friedman

Dear Ms. Axelrad:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 6,884,879. The application was filed on August 25, 2006, under 35 U.S.C. § 156. It is noted that patent term extension applications for the same regulatory review period for the human biological product, LUCENTIS® (ranibizumab), have been filed in U.S. Patent Nos. 6,407,213 and 7,060,269.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term extension. Thus, a determination by your office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Inquiries regarding this communication should be directed to the undersigned at (571)272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Till  
Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy

cc: Jeffrey P. Kushan  
Sidley Austin, LLP  
1501 K Street, N.W.  
Washington, DC 20005

RE: LUCENTIS® (ranibizumab)  
FDA Docket No. 2007E-0425